Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
Verastem, Inc.
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07644559CT.gov A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer | — | Recruiting | — | — | — |
NCT07349537CT.gov Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors | — | Recruiting | — | — | — |
NCT07223047CT.gov A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies | — | Recruiting | — | — | — |
NCT07020221CT.gov A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | — | Recruiting | — | — | — |
NCT06917079CT.gov BBO-11818 in Adult Subjects With KRAS Mutant Cancer | — | Recruiting | — | — | — |
NCT06835569CT.gov A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations | — | Recruiting | — | — | — |
NCT06585488CT.gov A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification | — | Terminated | — | — | — |
NCT06704724CT.gov A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. | — | Terminated | — | — | — |
NCT06607185CT.gov A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT06599502CT.gov A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation | — | Terminated | — | — | — |
Show 4 more trialsShow fewer
NCT06586515CT.gov MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors | — | Recruiting | — | — | — |
NCT06447662CT.gov A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. | — | Recruiting | — | — | — |
NCT06445062CT.gov Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | — | Recruiting | — | — | — |
NCT05039177CT.gov A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pancreatic Ductal Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cetuximab (this asset) | Verastem, Inc. | P2 | CCC · 55 |
| Daraxonrasib | Revolution Medicines, Inc. | P3 | BB |
| Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer | OHSU Knight Cancer Institute | P2 | BB |
| Rmc-6236 | Tango Therapeutics, Inc. | P3 | BB |
| S-1 | Genentech, Inc. | P2 | BB |
| Ivospemin | Panbela Therapeutics, Inc. | P2/3 | BB |
| Oxaliplatin | Jonsson Comprehensive Cancer Center | P4 | BB |
| (R)-(1-(4-Fluorophenyl)-6-((1-Methyl-1H-Pyrazol-4-Yl)Sulfonyl)-1,4,5,6,7,8-Hexahydro-4Ah-Pyrazolo(3,4-G)Isoquinolin-4A-Yl)(4-(Trifluoromethyl)Pyridin-2-Yl)Methanone | Corcept Therapeutics | P3 | BB |
| Metformin | British Columbia Cancer Agency | P2 | BB |
+42 more in the Pancreatic Ductal Adenocarcinoma cohort
Other indications for Cetuximab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colon Adenocarcinoma | — | P3 | BB · 70 |
| Rectal Carcinoma | — | P2 | BB · 69 |
| Non-Small Cell Lung Carcinoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- DaraxonrasibRevolution Medicines, Inc.BB
- Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, DimerOHSU Knight Cancer InstituteBB
- Rmc-6236Tango Therapeutics, Inc.BB
- S-1Genentech, Inc.BB
- IvospeminPanbela Therapeutics, Inc.BB
Citation
Floatz Terminal. Cetuximab in Pancreatic Ductal Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cetuximab-pancreatic-ductal-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →